

Peng Men

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9302306/publications.pdf>

Version: 2024-02-01

23
papers

293
citations

1040056

9
h-index

940533

16
g-index

23
all docs

23
docs citations

23
times ranked

495
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0146224.	2.5	92
2	Efficacy and Safety of Lomitapide in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 299-309.	2.2	24
3	Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. <i>Lipids in Health and Disease</i> , 2016, 15, 204.	3.0	22
4	Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0197321.	2.5	20
5	Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 144.	3.0	13
6	Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 696201.	3.5	13
7	Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6173-6184.	3.0	12
8	Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 107-115.	4.4	11
9	Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. <i>BMC Psychiatry</i> , 2018, 18, 286.	2.6	10
10	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2823-2831.	2.4	10
11	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 197.	2.8	9
12	A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?. <i>Hepatology International</i> , 2021, 15, 1356-1375.	4.2	8
13	Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting. <i>Medicine (United States)</i> , 2020, 99, e21559.	1.0	7
14	Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 46.	1.5	7
15	A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020). <i>Frontiers in Pharmacology</i> , 2022, 13, 845689.	3.5	7
16	Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles. <i>Frontiers in Public Health</i> , 2021, 9, 660514.	2.7	6
17	Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 774.	2.8	5
18	Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 469-480.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: A systematic review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1134-1142.	1.5	4
20	Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis. <i>Diabetes Therapy</i> , 2020, 11, 1745-1755.	2.5	4
21	Design, Synthesis, and Biological Evaluation of Novel Dual Inhibitors of Secretory Phospholipase A2 and Sphingomyelin Synthase. <i>Chinese Journal of Chemistry</i> , 2013, 31, 1164-1170.	4.9	3
22	Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 313-320.	1.4	1
23	Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. <i>Current Medical Research and Opinion</i> , 2020, 36, 213-217.	1.9	0